These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2392013)

  • 1. [Correlations of serum concentrations of CA 15.3 and estradiol in women with breast macrocystic disease].
    Vizoso F; Allende MT; Fueyo A; Vivanco J
    Med Clin (Barc); 1990 May; 94(20):798. PubMed ID: 2392013
    [No Abstract]   [Full Text] [Related]  

  • 2. [Correlation between blood concentrations of CA 15.3 and estradiol in women with macrocystic disease of breast. Study in function of the type of cyst].
    Vizoso F; Allende MT; Díez MC; Ruibal A
    Rev Clin Esp; 1991 Nov; 189(8):390-1. PubMed ID: 1784805
    [No Abstract]   [Full Text] [Related]  

  • 3. [The correlation between the serum concentrations of BCM (breast cancer mucin), CA549 and estradiol in women with breast macrocysts].
    Vizoso F; Allende MT; Fueyo A; Ruibal A
    Med Clin (Barc); 1991 Feb; 96(5):198. PubMed ID: 2033998
    [No Abstract]   [Full Text] [Related]  

  • 4. [Correlation of serum concentrations of BCM and MCA, CA 549 and CA 15.3 in women with macrocystic disease of breast].
    Vizoso F; Roiz MC; Allende MT; Ruibal A
    Med Clin (Barc); 1990 Mar; 94(8):319. PubMed ID: 2342398
    [No Abstract]   [Full Text] [Related]  

  • 5. Evidence of a correlation between CA15.3 and estradiol serum levels in women with fibrocystic (non macrocystic) mastopathy.
    Vizoso F; Allende MT; Diez MC; Ruibal A
    Int J Biol Markers; 1991; 6(1):33-4. PubMed ID: 1856515
    [No Abstract]   [Full Text] [Related]  

  • 6. [The correlation between the serum concentrations of CA 549 and CA 15.3 in patients with cystic breast disease].
    Allende MT; Vizoso F; Fueyo A; Ruibal A
    Rev Clin Esp; 1990; 187(3):152-3. PubMed ID: 2284494
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum androgen levels and the menstrual cycle in women with benign or malignant breast disease.
    England PC; Sellwood RA; Knyba RE; Irvine JD
    Clin Oncol; 1981 Sep; 7(3):213-9. PubMed ID: 6211319
    [No Abstract]   [Full Text] [Related]  

  • 9. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer].
    Bartel U; Johannsen B; Reiss H; Elling D
    Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between BCM (breast cancer mucin) and CA 549 serum levels cystic breast disease.
    Allende MT; Vizoso F; Roiz MC; Fueyo A; Ruibal A
    Int J Biol Markers; 1990; 5(1):48-9. PubMed ID: 2230352
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evaluation of danazol treatment of women with fibrocystic disease of breast].
    Baranowska B; Stopińska-Głuszak U
    Pol Tyg Lek; 1989 Aug 7-14; 44(32-33):771-3. PubMed ID: 2701752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of a correlation between CA15.3 and prolactin serum levels after TRH administration in women with gross cystic breast disease.
    Vizoso F; Allende MT; Fueyo A; Riera L; López Otin C; Ruibal A
    Int J Biol Markers; 1991; 6(1):31-2. PubMed ID: 1906915
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum prolactin levels in patients with fibrocystic breast disease.
    Peters F; Schuth W; Scheurich B; Breckwoldt M
    Obstet Gynecol; 1984 Sep; 64(3):381-5. PubMed ID: 6431348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum hormones in human breast cancer subjects.
    Krishnamoorthy G; Govindarajulu P; Ramalingam V
    Neoplasma; 1989; 36(2):221-31. PubMed ID: 2497392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of benign fibrocystic disease of the breast with 2-bromo-alpha-ergocryptine (CB 154).
    Santoro C; Cappa M; Moretti C; Fabbri A; La Vecchia V; Romano Marcellino L; Fraioli F
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):479-81. PubMed ID: 6815107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selenium in the blood of Japanese and American women with and without breast cancer and fibrocystic disease.
    Schrauzer GN; Molenaar T; Mead S; Kuehn K; Yamamoto H; Araki E
    Jpn J Cancer Res; 1985 May; 76(5):374-7. PubMed ID: 3924710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Levels of estrogen, progesterone, prolactin and sex hormone-binding globulin in the blood and breast cysts].
    Vlaisavljević V; Adamcic M
    Jugosl Ginekol Perinatol; 1986; 26(5-6):97-9. PubMed ID: 3657280
    [No Abstract]   [Full Text] [Related]  

  • 18. [Endocrine markers in benign breast diseases].
    Thalabard JC; Sitruk-Ware R; Kuttenn F; Mauvais-Jarvis P
    Zentralbl Gynakol; 1986; 108(6):354-8. PubMed ID: 3716674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA 15.3 behaviour in cystic breast disease.
    Vizoso F; Allende MT; Fueyo A; Vigal G; García-Morán M; Ruibal A
    Int J Biol Markers; 1989; 4(3):181-2. PubMed ID: 2614087
    [No Abstract]   [Full Text] [Related]  

  • 20. Adrenal steroids and tumor antigens in plasma and cyst fluid of women with gross cystic breast disease.
    Inaudi P; De Leo V; Baldini S; D'Antona N
    Ann N Y Acad Sci; 1990; 586():117-20. PubMed ID: 2356994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.